OneSource Q2FY27 revenue up 37% YoY, EBITDA surges 53%

OneSource Specialty Pharma reports robust Q2FY27 results with 37% YoY revenue growth and 53% YoY EBITDA jump. The strong performance reflects increased demand and operational efficiency in its specialty pharma segment. Investors may view this as a positive signal for future earnings trajectory.

📊 STOCKS: ONESOURCE | 🏢 SECTOR: Pharma | #HIGHIMPACT #Earnings